Jefferies puts ISTA on hold

Jefferies & Co., Inc. analyst David Windley rated ISTA Pharmaceuticals, Inc. at hold with the lowered price target of $6 as the company continues to find accelerating prescription growth difficult. ISTA's current strategy forces it into a cycle of raising capital with less and less favorable terms, according to the analyst. Second-quarter results were basically in line with the analyst's forecast. Shares of the Irvine, Calif.-based pharmaceutical company were down 4 cents, or 0.67%, at $5.94, on volume of 28,596 shares versus the three-month running average of 100,083 shares. (Nasdaq: ISTA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.